Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease

Abstract The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-p superfamily via a peripheral mode of administration. 5 According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive 10 agent. 4422738_i (GHMatters) P87733.AU 1